RO7204239, Risdiplam — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-10-28 in 3mo
ESTIMATED |
READOUT
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With
Phase 2/3 · Spinal Muscular Atrophy (SMA) |
Hoffmann-La Roche | RO7204239, Risdiplam |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|